AI in cell and gene therapy – a glimpse into the future while facing reality

“By identifying common rules across data sets and modalities, AI could help the field move from bespoke, heterogeneous products toward a more synthetic biology oriented approach.”

Cell and gene therapies (CGT) have gained medical acceptance because of their curative potential, yet patient access remains constrained by cost of goods, manufacturing and supply chain complexity, proximity to suitable hospitals, and development cycles complicated by patient to patient variability. Increasingly, AI is being positioned not as a peripheral addon, but as a foundational enabler for the field. It is my privilege to introduce this month’s edition of CGT Insights with an inaugural AI focus, where the authors explore how machine learning (ML) and AI can improve multiple stages of the therapeutic lifecycle.

Please enter your email to access content Read now